- Home
- SGHT vs BIOA Comparison
SGHT vs BIOA Comparison
Compare SGHT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGHT
- BIOA
- Stock Information
- Founded
- SGHT 2011
- BIOA 2015
- Country
- SGHT United States
- BIOA United States
- Employees
- SGHT N/A
- BIOA N/A
- Industry
- SGHT Medical Specialities
- BIOA Biotechnology: Pharmaceutical Preparations
- Sector
- SGHT Health Care
- BIOA Health Care
- Exchange
- SGHT Nasdaq
- BIOA Nasdaq
- Market Cap
- SGHT 193.2M
- BIOA 175.7M
- IPO Year
- SGHT 2021
- BIOA 2024
- Fundamental
- Price
- SGHT $5.82
- BIOA $7.26
- Analyst Decision
- SGHT Buy
- BIOA Hold
- Analyst Count
- SGHT 8
- BIOA 4
- Target Price
- SGHT $4.64
- BIOA $9.00
- AVG Volume (30 Days)
- SGHT 215.5K
- BIOA 667.0K
- Earning Date
- SGHT 11-06-2025
- BIOA 11-06-2025
- Dividend Yield
- SGHT N/A
- BIOA N/A
- EPS Growth
- SGHT N/A
- BIOA N/A
- EPS
- SGHT N/A
- BIOA N/A
- Revenue
- SGHT $76,052,000.00
- BIOA $5,917,000.00
- Revenue This Year
- SGHT N/A
- BIOA N/A
- Revenue Next Year
- SGHT $12.04
- BIOA N/A
- P/E Ratio
- SGHT N/A
- BIOA N/A
- Revenue Growth
- SGHT N/A
- BIOA N/A
- 52 Week Low
- SGHT $2.03
- BIOA $2.88
- 52 Week High
- SGHT $5.86
- BIOA $22.93
- Technical
- Relative Strength Index (RSI)
- SGHT 77.35
- BIOA 60.17
- Support Level
- SGHT $4.86
- BIOA $7.09
- Resistance Level
- SGHT $5.12
- BIOA $7.88
- Average True Range (ATR)
- SGHT 0.27
- BIOA 0.50
- MACD
- SGHT 0.03
- BIOA -0.01
- Stochastic Oscillator
- SGHT 95.56
- BIOA 59.28
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
About BIOA BioAge Labs Inc. Common Stock
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.